Evidence map›Paper›PMID 34496009›Full record

ArticleBlood advances2021

Restriction of HIV-1 infection in sickle cell trait.

Namita Kumari, Mehdi Nouraie, Asrar Ahmad, Hatajai Lassiter, Javed Khan, Sharmin Diaz, Nowah Afangbedji, Songping Wang, Patricia E Houston, Tatiana Ammosova and 14 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Does Sickle Cell Disease Protect against HIV Infection: A Systematic Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 1 country.

Namita KumariCenter for Sickle Cell Disease.ORCID 0000-0003-0893-9939
Mehdi NouraieDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.ORCID 0000-0001-7465-0581
Asrar AhmadCenter for Sickle Cell Disease.ORCID 0000-0002-4680-0033
Hatajai LassiterCenter for Sickle Cell Disease.
Javed KhanDepartment of Pediatrics, Howard University, Washington, DC.
Sharmin DiazCenter for Sickle Cell Disease.
Nowah AfangbedjiCenter for Sickle Cell Disease.
Songping WangCenter for Sickle Cell Disease.ORCID 0000-0003-4105-7700
Patricia E HoustonDepartment of Pediatrics, Howard University, Washington, DC.
Tatiana AmmosovaCenter for Sickle Cell Disease.
Miguel de Mulder RougvieDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-8026-7076
Sohail RanaCenter for Sickle Cell Disease.
Douglas F NixonDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-2801-1786
Kathryn AnastosMontefiore Medical Center, Bronx, NY.ORCID 0000-0002-0769-6405
Jason LazarSUNY Downstate Medical Center, Brooklyn, NY.
Audrey L FrenchDivision of Infectious Diseases, John H. Stroger Jr. Hospital of Cook County, Chicago, IL.
Stephen GangeJohns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.ORCID 0000-0001-7842-512X
Adaora A AdimoraInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0001-5035-1552
M Neale WeitzmannDivision of Endocrinology, Diabetes and Lipids, Department of Medicine, Emory University School of Medicine and The Atlanta VA Medical Center, Decatur, GA.ORCID 0000-0003-3305-5748
Margaret FischlDepartment of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0001-9241-5390
Mirjam-Colette KempfSchools of Nursing, Public Health and Medicine, University of Alabama at Birmingham, AL; and.
Seble KassayeDepartment of Medicine, Georgetown University, Washington, DC.ORCID 0000-0002-7527-7384
James G TaylorCenter for Sickle Cell Disease.ORCID 0000-0002-4421-1809
Sergei NekhaiCenter for Sickle Cell Disease.ORCID 0000-0003-0744-7887
Howard University · USCornell University · USEmory University · USGeorgetown University · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USMontefiore Medical Center · USSUNY Downstate Health Sciences University · USUniversity of Alabama at Birmingham · USUniversity of Miami · USUniversity of North Carolina at Chapel Hill · USUniversity of Pittsburgh · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Ellen Florence Eaton · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Sleep Disorders in Adults with Sickle Cell Disease: Frequency, Associations with Cardiovascular and Pain Indicators, and Responses to TreatmentU54MD007597 · NIMHD · HOWARD UNIVERSITY · PI BYRON D. FORD · 2019 to 2026
$37.7M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2M
NCATS NIH HHS UL1 TR000004NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R01 HL125005NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI087714NIAID NIH HHS P50 AI150476NIAID NIH HHS UM1 AI126617NIMHD NIH HHS G12 MD007597NIMHD NIH HHS U54 MD007597
6 · The paper itself

Abstract

Patients with sickle cell disease (SCD) have a lower risk for HIV-1 infection. We reported restriction of ex vivo HIV-1 infection in SCD peripheral blood mononuclear cells (PBMCs) that was due, in part, to the upregulation of antiviral, inflammatory, and hemolytic factors, including heme oxygenase-1 (HO-1). Here, we investigated whether individuals with sickle cell trait (SCT), who develop mild hemolysis, also restrict HIV-1 infection. Ex vivo infection of SCT PBMCs exhibited an approximately twofold reduction of HIV-1 replication and lower levels of HIV-1 reverse transcription products, 2-long terminal repeat circle, HIV-1 integration, and gag RNA expression. SCT PBMCs had higher HO-1 messenger RNA (mRNA) and protein levels and reduced ribonucleotide reductase 2 (RNR2) protein levels. HO-1 inhibition by tin porphyrin eliminated ex vivo HIV-1 restriction. Among Howard University clinic recruits, higher levels of HO-1 and RNR2 mRNA and lower HIV-1 env mRNA levels were found in SCT individuals living with HIV-1. To determine the population-level effect of SCT on HIV-1 prevalence, we assessed SCT among women living with HIV (WLH) in the WIHS (Women Interagency HIV-1 Study). Among WIHS African-American participants, the prevalence of SCT was lower among women with HIV compared with uninfected women (8.7% vs 14.2%; odds ratio, 0.57; 95% confidence interval, 0.36-0.92; P = .020). WIHS WLH with SCT had higher levels of CD4+/CD8+ ratios over 20 years of follow-up (P = .003) than matched WLH without SCT. Together, our findings suggest that HIV-1 restriction factors, including HO-1 and RNR2, might restrict HIV-1 infection among individuals with SCT and limit the pathogenicity of HIV.

Indexed as

Anemia, Sickle CellHIV-1HIV InfectionsSickle Cell TraitFemaleHumansLeukocytes, Mononuclear

Identifiers

PMID34496009
PMCPMC9153004
OpenAlexW3196402932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.